Innate Pharma SA [IPH] is a Biopharma company developing first-in-class immunotherapy drugs for cancer and inflammatory diseases. Its drug-candidates belong to a new class of therapeutic agents and consist of monoclonal antibodies aimed at immune regulatory checkpoints with a unique focus on the innate immunity compartment. This approach has been validated by two major Biopharma partners : Bristol-Myers Squibb in cancer and Novo Nordisk A/S in inflammation.

Biopharmaceuticals

Denis Lucquin

Denis Lucquin is a Managing Partner  of Sofinnova Partners. In life sciences, he specializes in industrial biotechnology investments. He joined Sofinnova in 1991. Denis began his career in academic research. For five years, he was in charge of the technology transfer department at the Institut Natio...